Key Takeaways Technological advancements in sacral neuromodulation include MRI-conditional devices, rechargeable systems, and extended battery lifespans, enhancing patient eligibility and reducing ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different ...

Physician Summary: Real-World Data on Nadofaragene Firadenovec in BCG-Unresponsive NMIBC A recent study by Moyer et al (2025) provides real-world data on the efficacy and safety of nadofaragene ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Video content above is prompted by the following: Practice Updates and Treatment Approaches in Non-Muscle Invasive Bladder Cancer Panel Introduction Moderator: Dr Ashish Kamat - University of Texas MD ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

Physician Summary: Specific tumor features—such as papillary architecture and the presence of carcinoma in situ (CIS)—play a critical role in shaping treatment decisions for NMIBC. Papillary tumors, ...